Oncothyreon Advances to Phase 2 Portion of Phase 1/2 Trial of PX-866 in Combination with Cetuximab

Oncothyreon Inc. ONTY today announced it has initiated the Phase 2 portion of its ongoing Phase 1/2 trial of PX-866 in combination with the chimeric monoclonal antibody cetuximab following successful completion of the Phase 1 dose escalation portion of the study. PX-866 is a small molecule compound designed to inhibit the activity of phosphatidylinositol-3-kinase, a component of an important cell survival signaling pathway.